New drug GEn-1124 tested in just 6 men – first look at how body handles it

NCT ID NCT07185113

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a single oral dose of GEn-1124 in 6 healthy adult men. Researchers measured how the drug moves through the body and checked for any side effects. Participants stayed in the clinic for 2 days and received follow-up phone calls. The goal was to gather basic safety and processing information, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

GEn-1124 (oral capsule)

What could go wrong

This is a very early, small study in just 6 healthy men. It only looks at how the drug moves through the body and basic safety, not whether it treats any disease. Many early-stage drugs never advance.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT MALE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • New Zealand Clinical Research (NZCR)

    Christchurch, 8011, New Zealand